Related Experiment Video

Updated: May 8, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Genetic polymorphism G894T and the prognosis of heart failure outpatients

Oziel Marcio Araujo Tardin, Sabrina Bernardez Pereira, Monica Wanderley Monçores Velloso

    Arquivos Brasileiros De Cardiologia
    |August 17, 2013
    PubMed

    Insights

    This study found no link between the G894T gene variant and heart failure outcomes in Brazilian patients. Further research is needed to understand genetic factors influencing heart failure prognosis.

    Area of Science:

    • Cardiology
    • Genetics
    • Molecular Biology

    Background:

    • Endothelial nitric oxide synthase (eNOS) genetic polymorphisms have been studied for their impact on heart failure prognosis.
    • Previous research has not specifically investigated the G894T polymorphism in relation to heart failure within the Brazilian population.

    Purpose of the Study:

    • To investigate the association between the G894T polymorphism of endothelial nitric oxide synthase and the prognosis of heart failure in Brazilian outpatients.
    • To determine if G894T genotype or allele frequencies correlate with clinical outcomes such as reverse remodeling, functional class improvement, mortality, and hospitalization rates.

    Main Methods:

    • A cohort study involving 145 Brazilian patients with systolic heart failure, followed for up to 40 months.
    • Evaluation of G894T polymorphism using polymerase chain reaction and restriction fragment length polymorphism.
    • Assessment of outcomes including left ventricular reverse remodeling, New York Heart Association (NYHA) functional class, mortality, and hospitalization rates.

    Main Results:

    • Genotypic frequencies were GG (40%), GT (48.3%), and TT (11.7%). Allele frequencies were guanine (64.1%) and thiamine (35.8%).
    • No significant differences in genotype or allele frequencies were observed based on self-declared race.
    • No statistically significant relationship was found between G894T genotype or allele frequencies and the evaluated heart failure outcome measures.

    Conclusions:

    • The G894T polymorphism (Glu298Asp) in endothelial nitric oxide synthase does not appear to be associated with the prognosis of systolic heart failure in this Brazilian cohort.
    • These findings suggest that the G894T variant may not be a significant predictor of heart failure outcomes in the Brazilian population studied.
    Abstract

    More Related Videos

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

    Published on: April 1, 2019

    Related Concept Videos

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Heart Failure IV: Classification and Diagnostic Evaluation01:30

    Heart Failure IV: Classification and Diagnostic Evaluation

    Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    Principles of Pharmacogenetics: Types of Genetic Variants01:27

    Principles of Pharmacogenetics: Types of Genetic Variants

    The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

    Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

    The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...